The G Protein-Coupled Receptor Latrophilin-2, A Marker for Heart Development, Induces Myocardial Repair After Infarction.

Discovering cell-surface markers based on a comprehensive understanding of development is utilized to isolate a particular cell type with high purity for therapeutic purposes. Given that latrophilin-2 (Lphn2) substantially contributes to cardiac differentiation, we examined whether Lphn2 regulates functional significance in heart development and repair. We performed whole-mount immunostaining followed by clearing technique of embryo, RNA sequencing related to Lphn2-knockout (KO) embryo, and in vivo functional analyses of Lphn2+ cells using echocardiography. After immunostaining the cleared embryo sample, Lphn2 was exclusively observed in cardiac cells expressing α-sarcomeric actinin at embryonic days E9.5 and E10.5. Homozygous Lphn2-KO mice were embryonically lethal and showed underdevelopment of the ventricular myocardium. However, Lphn2 was not required to develop vessels, including endothelial cells and smooth muscle cells. For the purpose of cardiac regeneration, we transplanted pluripotent stem cell (PSC)-derived Lphn2+ cells into the infarcted heart. PSC-derived Lphn2+ cells differentiated into cardiomyocytes and regenerated the myocardium when transplanted into the infarcted heart, unlike Lphn2- cells. Transplanted Lphn2+ cells improved left-ventricle systolic function and reduced infarct size. We demonstrated that Lphn2 exhibits potential as a cardiomyogenic marker to facilitate targeted stem cell therapy for heart repair in clinical practice.

This study demonstrated that Lphn2 exhibits potential as a cardiomyogenic marker to facilitate targeted stem cell therapy for heart repair in clinical practice. The utilization of pluripotent stem cell-derived Lphn2+ cells could provide a targeted approach to regenerate myocardium after ischemic injury in clinical practice.

Introduction

Among cardiovascular diseases, ischemic heart failure, including myocardial infarction, is the most common, and its prevalence has been increasing.[1] Numerous studies have been conducted to overcome heart disease, but current medical treatment has a definite limitation to solve this global health issue.

In patients with myocardial infarction, the number of cardiomyocytes is significantly reduced due to cell death. Cardiomyocytes exist in a constant number over the life of a human being and have a slow dividing capacity of less than 1% per year and a limited ability to regenerate.[2] When the myocardium is damaged, there is no way to repair it other than externally supplying cardiomyocytes. It is challenging to deliver human pluripotent stem cell (PSC)-derived cardiomyocytes to the damaged heart, and the adult heart lacks endogenous cardiac stem and progenitor cells that can regenerate.[3,4] Therefore, there has recently been an increasing demand for PSC–derived cardiomyocytes for cardiovascular disease and cell therapy studies.[5]

Recently, we identified cardiac–lineage markers, latrophilin-2 (Lphn2)[6,7] and lysophosphatidic acid receptor 4 (LPAR4)[8] as G protein–coupled receptors (GPCRs). However, LPAR4 expression was transient during cardiac differentiation from the undifferentiated state of PSCs. GPCRs are well-known to function in nervous system development and disease, metabolism, cancer.[9-11] GPCRs comprise the largest family of seven-transmembrane receptors, and there are more than 800 members of GPCRs discovered in humans.[12] In the case of adhesion GPCR, Lphn2 is separately classified as subfamily B2 due to its GPCR autoproteolysis–inducing domain that can self-cleavage.[13]

The influence of specific GPCRs on stem cell therapy for heart repair in clinical practice has not been reported, although GPCRs are well-known regulators of cardiac function.[14] Latrophilins include three adhesion GPCRs (Lphn1–Lphn3) that contain large extracellular sequences, a seven-TMR-domain typical of GPCRs, and a relatively long intracellular tail.

In this study, we demonstrate that Lphn2 is a functional marker of cardiomyocytes and heart development. Furthermore, we show that PSC–derived Lphn2+ cells have therapeutic potential for damaged hearts.

Materials and Methods

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Actin-GFP iPS Cell Generation

Skin fibroblasts from Actin-promoter driven GFP TG mice (C57BL/6-Tg(CAG-EGFP)1Osb/J) were cultured in DMEM (Invitrogen) high glucose supplemented with 10% FBS (Invitrogen), 1% antibiotic-antimycotic (Invitrogen) on the plate (5% CO2, 37 °C). FUW–based lentiviral vectors (FUW-tetO-OSKM: Oct4/Sox2/Klf4/C-Myc and M2rtTA; Addgene) were transfected into 293T cells using PEI (polyethylenimine; Sigma). The viral medium was harvested at 48h following transfection and filtered through 0.45-μm pore filters. For concentration, viral supernatant was ultracentrifuged at 107170 g for 1.5h at 4 °C, and the pellets were resuspended in an appropriate transduction medium. Virus soup was used to transduce skin fibroblasts (isolated from Actin-promoter driven GFP TG mice) with polybrene (10 μg/mL). Twenty-four hours after transduction, the mESC medium was replaced. The mESC medium was composed of DMEM (Invitrogen) with 2mM L-glutamine, 10% FBS (Invitrogen), 0.1mM β-mercaptoethanol (Sigma–Aldrich), 1% non–essential amino acids (Invitrogen), 50 IU/mL penicillin, 50mg/mL streptomycin (Invitrogen), and 2000 U/mL (20ng/mL) recombinant LIF (Millipore, Cat. #: ESG1107). To initiate reprogramming, the medium was changed to mESC medium containing 2 μg/mL doxycycline. Media was changed daily until ES–like colony was formed. Actin-GFP iPSCs were cultured on a mitomycin C (Sigma–Aldrich)–treated MEF (ATCC, Cat. #: SCRC-1040) feeder layer in gelatin (Sigma–Aldrich)–coated tissue culture dishes at 37 °C and 5% CO2 in an air atmosphere.[15]

Induction of Myocardial Infarction and Cell Transplantation

To generate myocardial infarction, 8 weeks old athymic nude mice were anesthetized with zoletil (91mg/kg, Virbac Laboratories) and xylazine (11.65mg/kg, Bayer), intubated, and artificially ventilated (Harvard apparatus).[16] The chest was opened and the left anterior descending branch was ligated using 8-0 polypropylene. Immediately after LAD ligation, 1×105 cells from the respective groups were directly injected into the peri-infarct area.[16-19] The same volume of PBS was injected in an identical fashion as a control. After 14 days the mouse heart was evaluated by echocardiographic examination and harvested.

Statistical Analysis

SPSS version 18.0 (SPSS Inc.) was used for all statistical analyses. All experiments were performed at least three times independently. In all cases, multiple experiments were performed independently to verify the reproducibility. The number of samples (n) used in each experiment is indicated in the legend or shown in the figures. The results are presented as the mean ± standard error of the mean. Statistical analyses between two groups were conducted using the unpaired t-test or the Mann–Whitney U test, as appropriate. Comparison of more than two groups was performed using a one-way ANOVA. If the F test results were <0.05, post hoc comparisons were performed with the Bonferroni test. Statistical significance was defined as P < .05 and indicated as ∗P < .05, ∗∗P < .01. For animal studies, the sample size for experiments was determined empirically based on previous studies to ensure appropriate statistical power. Mice in the study were randomly chosen for myocardial infarction. No animals were excluded from statistical analysis, and the investigators were blinded in the studies.

Results

Expression of Lphn2 in the Embryonic Development and Adult Cells and Tissues

To verify whether Lphn2 is a cardiac–specific marker during development, we assessed its expression in mouse embryos using the clearing technique.[20] After immersion in a solution with a refractive index matching that of the clearing in the hybrid system, the mouse embryo became transparent (Fig. 1A). After immunostaining the transparent embryo sample, Lphn2 was exclusively stained in cardiac cells expressing α-sarcomeric actinin (α-SA) at embryonic day (E) 9.5 (Fig. 1B; Supplemental online Video 1) and E10.5 (Fig. 1C; Supplemental online Video 2). Lphn2 was stained in the ventricle and atrium at E9.5, whereas Lphn2 was present in all heart chambers at E10.5. Next, we isolated single adult cardiomyocytes from the left ventricle of the heart of wild-type C57BL/6 mice and transgenic mice expressing enhanced yellow fluorescence protein (EYFP) under the alpha myosin heavy chain (Myh6) promoter, using collagenase with the Langendorff perfusion system, and assessed Lphn2 expression. Cardiomyocytes from the adult mouse heart expressed Lphn2 on their surfaces (Fig. 1D).

Figure 1.

Lphn2 expression in mouse embryonic heart tissues, adult cardiomyocytes, and adult heart tissues. (A): Before and after images of a cleared mouse embryo (E10.5) prepared by fixing in paraformaldehyde, embedding in a hydrogel, electrophoretic tissue clearing, and refractive-index matching. (B): Three-dimensional rendering of a clearing-processed whole mouse embryo (E9.5), imaged by confocal microscopy for Lphn2 (green), α-SA (red), and merged expression. Blue, nuclear counterstain (DAPI). Scale bar, 500 μm. (C): Immunostaining of a clearing-processed embryonic heart (E10.5) for Lphn2 (green) and α-SA (red). Blue, nuclear counterstain (DAPI). Scale bar, 200 μm. OFT, outflow tract; V, ventricle; A, atrium. (D) Cytospin/immunostaining for Lphn2 in adult cardiomyocytes extracted by the Langendorff perfusion method from wild–type mice and Myh6 promoter–driven EYFP mice. Blue, nuclear counterstain (DAPI).

We further analyzed the expression of Lphn2 mRNA in various cell types. Of interest, the qPCR analysis revealed that Lphn2 was highly expressed in mESC–derived cardiomyocytes as well as primary cultured neurons and neuronal stem cells (NSCs) (Supplementary Figure S1A). Consistent with our qPCR results, IF staining did not exhibit Lphn2 expression in mouse Hepa1c1c7 or C2C12 cells; however, Lphn2 was expressed only in the central nervous system (CNS)–related cells, including primary neurons and NSCs (Supplementary Figure S1B). Furthermore, since fibroblasts are converted to myofibroblasts in response to tissue injury or upon transforming growth factor (TGF)-1β stimulation,[21] we performed IF staining in primary–cultured cardiac fibroblasts to assess Lphn2 expression. IF analysis revealed Lphn2 expression neither in quiescent fibroblasts nor in myofibroblasts expressing smooth muscle actin (SMA) (Supplementary Figure S1C).

We also examined the heart after myocardial infarction and detected Lphn2 expression on cardiomyocytes expressing α-SA in the peri-infarct area (Supplementary Figure S2A). Interestingly, Lphn2-positive cells did not express either SMA or isolectin B4 (ILB4), which are markers for vascular smooth muscle cells and endothelial cells, respectively (Supplementary Figure S2B). Previously, Lphn2 was detected in multiple organ tissues of adult mice.[22] We performed qPCR and western blotting analysis to confirm the gene and protein expression levels of Lphn2, respectively, in multiple adult organs. Lphn2 was not detectable at the mRNA or protein level in most tissues but was enriched in the brain, heart, and lung (Supplementary Figure S3A, B). Also, we performed qPCR of embryonic and adult hearts to compare the expression patterns of Lphn2. Interestingly, a higher expression of Lphn2 was found in the developing embryonic heart than in the adult heart, strongly suggesting a critical role of Lphn2 in cardiogenesis (Supplementary Figure S4).

We then analyzed LPHN2 expression in human heart tissues. IF staining demonstrated that LPHN2 was present in cardiomyocytes (α-SA+), but not in smooth muscle cells (SMA+) or endothelial cells (UEA1-Lectin+) (Supplementary Figure S5). Taken together, these data indicate that Lphn2 is highly expressed on cardiomyocytes and heart tissues in both mice and humans.

Lphn2 Shows Functional Significance as the Master Regulator of Heart-Development Genes

To examine the functional significance of Lphn2 in development, we generated Lphn2-KO mice using Lphn2-KO ESCs. Lphn2 heterozygous mice (Lphn2+/−) were alive and fertile. When we tried to generate complete KO mice through the mating of Lphn2+/− mice, the homozygous Lphn2-deficient fetus (Lphn2−/−) was embryonically lethal after E15.5. We extracted total RNA from wild-type and Lphn2 homo-KO (−/−) embryos at E9.5 and performed RNA sequencing (RNA-Seq) analysis to explore gene expression differences associated with defects in heart development (Supplementary Figure S6). Intriguingly, most genes associated with heart development were downregulated in Lphn2−/− embryos (Fig. 2A). The expression of genes responsible for atrioventricular valve morphogenesis, embryonic heart tube development, outflow tract morphogenesis, and ventricular cardiac muscle tissue morphogenesis was lower in Lphn2−/− embryos than in wild-type embryos (Fig. 2B).

Figure 2.

Expression of heart–specific genes by RNA sequencing method in Lphn2 KO embryos. (A): RNA sequencing of whole embryonic tissues obtained from six samples of wild-type and Lphn2-homozygous (−/−) knockout embryos at E9.5 and gene clustering using MeV 4.9.0. Hierarchical cluster analyses were carried out with Euclidean distance correlation as the distance measurement with average linkage. Downregulated and upregulated genes in Lphn2−/− KO embryos are shown in green and red, respectively. Dysregulated genes with a >2-fold change in expression and with a P-value < .05 are shown (n = 3). (B): Heat map showing mRNA expression of gene ontology representing heart development, embryonic heart tube development, atrioventricular valve morphogenesis, outflow tract morphogenesis, and ventricular cardiac muscle tissue morphogenesis in six samples of wild-type and Lphn2−/− KO embryos at E9.5. To perform gene–annotation enrichment analysis, the genes were selected and input using the DAVID functional annotation tool.

To examine the use of Lphn2 as a bona fide CPC marker during heart development, we assessed Lphn2 expression during early embryonic development. The heart of Lphn2−/− embryos at E11.5 exhibited underdevelopment of the ventricular myocardium and disrupted conotruncal development without any abnormality in the atrial chambers. Also, its Gata4 expression was not as high as that in wild–type embryos (Fig. 3A). Furthermore, at E14.5, unlike the hearts of wild-type, those of Lphn2−/− embryos revealed extensive underdevelopment of the myocardium, such that endocardial trabeculation was not visible (Fig. 3B). Conotruncal septation was also affected, and the endocardial cushion tissue at the aortic and pulmonary valves was not separated from the surrounding myocardium. Again, the right and left atrial myocardium and chambers were well developed, and the aorta and pulmonary trunks were also well-formed (Fig. 3B). After immunostaining of the cleared wild–type embryo, Lphn2 was exclusively observed in the four cardiac chambers and outflow tract expressing α-SA at E14.5 (Fig. 3C; Supplemental online Video 3). However, Lphn2−/− embryos exhibited abnormal heart development, with smaller ventricular mass at E14.5 (Fig. 3C; Supplemental online Video 4).

Figure 3.

Functional significance of Lphn2 in cardiac development. (A): Expression pattern of Lphn2 overlap with early cardiac markers in heart development. Immunostaining of Lphn2 (green), Gata4 (red), and α-SA (white) in the heart of wild-type, Lphn2, and Lphn2− embryos at E11.5. Blue, nuclear counterstain (DAPI). Scale bar, 200 µm. LV, left ventricle; OFT, outflow tract; RA, right atrium; RV, right ventricle. (B): Representative H&E-stained transverse sections revealed the disrupted conotruncal septation of ventricles in Lphn2−/− KO embryos at E14.5. All embryos were from the same litter. Scale bars, 20 µm, LA, left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle. (C): Immunostaining of a clearing-processed heart of wild-type and Lphn2−/− KO embryos at E14.5 for Lphn2 (green) and α-SA (red). Blue, nuclear counterstain (DAPI). LA, left atrium; RA, right atrium; LV, left ventricle; RV, right ventricle; OFT, outflow tract.

Next, we determined whether Lphn2 is involved in the development of other tissues, including vessels, neurons, and the liver. No differences were observed in SMA expression in vascular smooth muscle cells or ILB4 in endothelial cells among wild-type, Lphn2+/−, and Lphn2−/− embryos (Fig. 4A, B). There were no differences in the ectoderm (neuron, βIII-tubulin) and endoderm (liver, HepPar1) development among wild-type, Lphn2+/−, and Lphn2−/− embryos (Fig. 4C, D), demonstrating that Lphn2 is not required for the development of other tissues, including vessels. We additionally performed immunofluorescent staining to validate the ectoderm expression during the embryonic development. As expected, there were no differences in Glial Fibrillary Acidic Protein (GFAP) expression of neuronal astrocytes in the brain among wild-type, Lphn2+/−, and Lphn2−/− embryos (Supplementary Figure S7A). There were also no differences in the endoderm (liver, albumin) development among wild-type, Lphn2+/−, and Lphn2−/− embryos (Supplementary Figure S7B). In addition, we performed the additional qPCR experiment to validate the reproducibility of the IF data for a subset of ectoderm–related genes (NeuroD1, GFAP, Nestin, and Dab2) or endoderm–related genes (ALB, AFP, Foxa2, and Ihh) in whole-body tissue at embryonic day 13.5. qPCR analysis showed that there was no significant difference between the 3 groups (WT embryo vs. Lphn2-hetero KO embryo vs. Lphn2-homo KO embryo) (Supplementary Figure S8).

Figure 4.

Role of Lphn2 in mesodermal, ectodermal, and endodermal development of embryos. (A, B): Immunostaining of non-myogenic, vascular lineage markers SMA (A) and ILB4 (B) in wild-type and Lphn2–KO embryos at E11.5. Scale bars, 1000 µm (C): Expression of βIII-tubulin, an ectoderm lineage marker, in wild-type, Lphn2+/− and Lphn2−/– embryos at E11.5. (D): Expression of HepPar1, a hepatic endoderm marker, in wild-type, Lphn2+/− and Lphn2−/− embryos at E11.5. Scale bar, 20 µm.

Collectively, these data indicate that Lphn2-expressing CPCs play a significant role in generating the heart, acting as cardiac muscle progenitors that play roles different than those of previously described multipotent CPCs.[23-26]

Lphn2 has Therapeutic Potential to Induce Myocardial Repair after Infarction

We investigated the in vivo differentiation potential and therapeutic efficacy of iPSC–derived Lphn2+ CPCs. To evaluate how Lphn2+ cells can engraft and survive into infarct hearts, we generated green fluorescent protein (GFP)–expressing iPSCs from the skin fibroblasts of Actin promoter–driven GFP transgenic mice (Fig. 5A). Upon sorting cells depending on the Lphn2 and GFP expression after 7 days of differentiation of iPSCs toward CPCs, we could significantly attain enrichment of cardiac lineage cells in the Lphn2+ population and exclusion of cardiac lineage cells from the Lphn2− cell population. Lphn2+ cells at day 7 expressed cardiac lineage markers but did not contract spontaneously, indicating that the cells were in the CPC stage rather than being mature cardiomyocytes. Next, we induced myocardial infarction by ligating the left coronary artery, following which we injected 1×105 cells into the peri-infarct area.

Figure 5.

Therapeutic potential of Lphn2 to repair the heart after infarction. (A): Experimental scheme to assess the therapeutic efficacy of iPSC-derived Lphn2+ cells using a mouse myocardial infarction model. iPSCs were generated from primary skin fibroblasts isolated from Actin-GFP transgenic mice. iPSC-derived GFP+/Lphn2+ or GFP+/Lphn2− cells were sorted at day 7 after cardiac differentiation and transplanted into the peri-infarct area. (B): Masson’s trichrome staining was performed two weeks after the injection of PBS, iPSC-derived Lphn2+ cells, and Lphn2− cells into the peri-infarct zone of the heart after ligation of the left coronary artery (n = 15 per group). (C): Echocardiographic parameters at 14 days after cell transplantation (∗∗P < .01, ANOVA test and post hoc Bonferroni test, n = 10 per group). LVESD, LV end-systolic dimension; LVEDD, LV end-diastolic dimension; LVFS, LV fractional shortening; LVEF, LV ejection fraction. (D): Immunostaining of mouse myocardial infarction heart tissues injected with PBS, iPSC-derived Lphn2+ cells, and Lphn2− cells. Injected GFP+ cells were traced and immunostained for GFP (green), Lphn2 (red), and α-SA (white). Blue, nuclear counterstain (DAPI). White rectangles in the upper images indicate regions shown at higher magnification from the lower image. Scale bars, 200 µm (upper panels) or 50 µm (lower panels).

Two weeks later, Masson’s trichrome staining showed that the LV wall was replaced by a sizeable fibrotic scar and that the LV dimension was markedly enlarged in the PBS–injected group (Fig. 5B). In contrast, the infarcted heart transplanted with Lphn2+ cells showed several engrafted nodules that had replaced the LV wall and reduced the infarct size (Fig. 5B). Transplantation of Lphn2+ cells significantly reduced the fibrosis area and length compared with those in the PBS–injected control group and Lphn2− cells (Supplementary Figure S9A). Echocardiography revealed significantly small LV dimensions at the systole and diastole, and the LV systolic function was higher in the Lphn2+ cell group than in the PBS–injected control and Lphn2− cell groups (Fig. 5C).

Importantly, immunostaining analysis showed that transplanted GFP+/Lphn2+ cells in the infarct zone were differentiated into α-SA+ cardiomyocytes (Fig. 5D). Two weeks later, most GFP+/Lphn2+ cells expressed α-SA as a cardiac myocyte marker, but in unorganized patterns, implying that the engrafted cells were still CPCs or had differentiated into immature CMCs (Supplementary Figure S9B, C). Although GFP+/Lphn2− cells successfully engrafted into the peri-infarct area, they did not differentiate into cardiomyocytes and did not improve the myocardial infarction (Fig. 5D; Supplementary Figure S9B, C). Immunostaining showed that grafted GFP+/Lphn2− cells were primarily endoderm–lineage cells (Supplementary Figure S10A). Undifferentiated Actin-GFP-iPSCs formed large masses inside and outside the LV, reflecting the formation of a teratoma with the potential to differentiate into three germ layers (Supplementary Figures S10B, S11). In the PBS–injected control group, α-SA+ cardiomyocytes in the host myocardium of the peri-infarct zone expressed endogenous Lphn2 at day 14 (Figure 5D; Supplementary Figure S9B, C).

Consequently, these findings suggest that PSC–derived Lphn2+ cells function as cardiomyogenic progenitor cells and may be viable candidates for the regeneration and repair of damaged hearts.

Discussion

In this study, we confirmed that Lphn2 is highly expressed in the mouse brain and heart. In our previous study, we found that Lphn2 is a unique marker of cardiac progenitor cells and cardiomyocytes derived from PSCs.[7] Although Lphn2 has been implicated in the CNS, our study identified Lphn2 as a novel marker for cardiomyocytes in the embryonic and adult heart. Moreover, we demonstrated that Lphn2 expression is more specific to the brain and heart, rather than ubiquitously expressed in adult tissues.

Unlike the previously reported ubiquitous expression throughout adult tissues,[22,27] our qPCR analysis showed that Lphn2 was highly expressed in both neuronal stem cells and primary cultured neurons. Also, IF staining of multiple cell types demonstrated that Lphn2 expression did not appear in mouse Hepa1c1c7 and C2C12, but appeared only in primary neurons and neuronal stem cells. Of interest, Lphn2 gene and protein were not detectable in most tissues but enriched in the brain, heart, and lung. In vivo, Lphn2 was only expressed in the heart during the embryonic developmental stage, but in the adult, it was expressed in the brain as well. Thus, for the first time, we report the unverified functional role of Lphn2 in heart development and adult damaged heart.

The clearing is a transparency technique of intact biological tissue using acrylamide–based hydrogels by removal of lipids.[20] Whole-mount embryo immunostaining with clearing showed that Lphn2 is expressed in the heart with three-dimensional and topological morphologies during the developmental stage. Our clarified 3D images and movies show that four chambers expressed Lphn2 of the heart are fully developed at E10.5 but not at E9.5. Since we established a powerful imaging analysis method with the clearing technique, it could be very informative to acquire 3D images of the heart in Lphn2 homo-knockout embryos rather than 2D images of sections, which do not allow for accurate analysis of organ morphology. Therefore, we presume the spatial and temporal distributions of Lphn2 follow a stepwise development of the heart. Furthermore, the gene expression patterns of RNA-Seq data for whole embryonic tissues from Lphn2−/− mice support our findings of developmental defects, demonstrating that Lphn2 is a significant inducer of central transcription factors for heart development. These data indicate that Lphn2 is a critical gene for cardiomyogenic progenitor cells and is essential for the successful development of embryos with fully mature cardiomyocytes.

Genetic mutations in TBX5, NKX2-5, and GATA4 cause congenital heart diseases (CHDs) such as Holt-Oram syndrome, atrial septal defects, and ventricular septal defects.[28-30] Additionally, a recent study has shown that TBX20, which is known to interact with cardiac transcription factors such as GATA4, NKX2-5, and TBX5,[31] is involved in the pathogenesis of left ventricular non-compaction cardiomyopathy.[32] Our RNA-Seq analysis showed markedly reduced expression of Gata4, Nkx2.5, Tbx5, and Tbx20 in Lphn2−/− embryos, suggesting that there could be pathological implications in humans. Since mouse Lphn2 is highly homologous to the human protein, our results have implications for congenital heart disease and regenerative cell therapy to restore lost cardiac muscles.

The present results suggesting that Lphn2 is a therapeutic target in myocardial infarction are based on studies using Lphn2–KO mice. Therefore, the significance of Lphn2 in the pathophysiology of heart disease should be further investigated in genetically modified models, such as in inducible cardiac–specific KO mice or heterozygous Lphn2–KO mice. These strategies will enable predicting which phenotype appears when Lphn2 is knocked out at a particular developmental stage and how cardiac physiology changes when Lphn2 is knocked out in the post-natal or adult stage. Further study is also needed to determine the phenotype under various physiological conditions, such as myocardial infarction in living and fertile heterozygous Lphn2–KO mice.

Conclusion

In summary, we have demonstrated that Lphn2 exhibits potential as a cardiac–specific lineage marker to facilitate targeted stem cell therapy for heart repair. Furthermore, this study’s results could be of potential use in regenerative medicine to restore cardiac muscle.

Click here for additional data file.

Click here for additional data file.

Click here for additional data file.

Click here for additional data file.

Click here for additional data file.